Board Director Invests $1.5 Million in Xencor Inc (XNCR) Amid the IPO

On Friday, Xencor Inc (NASDAQ:XNCR)’s Board Director, John Stafford III acquired 275,000 company shares at its initial public offering (IPO). He paid the full IPO price, $5.50 per share, in a transaction worth more than $1.5 million. These shares add up to the ones he got in exchange for his Series A-1 Preferred Stock (every 3.1 shares of Series A-1 Preferred Stock automatically converted into 1 share of common stock).

Xencor

Xencor Inc (NASDAQ:XNCR) is a small-cap clinical-stage biopharmaceutical company that develops engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma, allergic diseases, and cancer, closed its IPO last Friday, Dec 6th. It offered 14,639,500 shares of its common stock at an IPO price of $5.50 per share. After deducting underwriting discounts and commissions, and estimated offering expenses, the company projects net proceeds from the offering to be around $72.4 million.

Since the opening of the IPO, several forms reporting insider trades have been filed with the U.S. Securities and Exchange Commission. However, most of them have been disclosures from Board directors and major shareholders, who received the new, publicly traded, stock of Xencor Inc (NASDAQ:XNCR) in exchange for their Series A-1 Preferred Stock.

Back to Stafford: the director now holds more than 7.8 million shares of common stock, valued at more than $64 million. As the owner of more than 25% of the outstanding shares, Stafford stands as the largest shareholder after the IPO. In fact, he was already the largest stockholder before the company went public, owning 45.2% of the company’s shares, according to Xencor Inc (NASDAQ:XNCR)’s S-1 form. In addition, John Stafford, Jr, owned an extra 10.3%, and James Stafford another 6.2%. They now own 5.9% and 3.4% of the total shares, respectively.

Other strong betters on Xencor Inc (NASDAQ:XNCR) are Atul Saran and R Harold Werner, Board Directors, and MedImmune Ventures, Inc. However, currently, none of the major hedge funds that we track hold stakes in this biopharmaceutical company. Still, this could be explained, not by a lack of bullish sentiment, but by the very little time passed since the company went public. Nonetheless, its negative figures for margins and returns are eye-catching: investors should be aware of the risks involved in investing in a clinical-stage biopharmaceutical company.

One way or another, stock is on the rise now, and could certainly be a good play, at least for short-sellers.

 

Disclosure: Javier Hasse holds no position in any stocks mentioned

Recommended Reading:

Akamai Technologies, Inc. (AKAM)’s CEO Buys Stock Amid M&A Announcement

Insiders Feeling Good With These Healthcare Stocks

Insiders and Jim Simons Into IT Services

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

Qihoo 360 Technology Co Ltd (QIHU), Actavis plc (ACT), Yahoo! Inc. (YHOO) Among 20 Long Ideas from Sohn Canada

The 10 Laziest Countries in the World

The 10 Most Polluted Countries in the World

The 10 Most Dangerous Cities in America 2014

The Top 10 Gold Producing Countries in the World

The 10 Tallest Buildings in the World

The 10 Richest Stand Up Comedians in the World

The 10 Fattest Countries in the World

The 5 Best Summer Jobs for Teens

The 10 Most Religious Countries in the World Keeping the Faith

The 10 Most Educated Countries in the World

The 10 Most Popular Cell Phones in the World

The 10 Drunkest Countries in the World

The 10 Most Expensive Private Schools in the World

The 10 Smallest Countries in the World

Walking Dead Season 5 Spoilers You’ll Wish You Didn’t Know

The 10 Poorest Countries in the World

The 10 Greenest Countries in the World

The Top 10 Countries with the Highest Population in the World

The 10 Most Visited Countries in the World

The Top 10 Star Wars Characters in the Iconic Series

The 10 Most Expensive Android Phones in the World

5 Reasons Why The Illuminati Is Real and a Threat to Society

The 6 Scariest Halloween Costumes Ever Screamed At

The 4 Biggest Hedge Fund Managers in the World Today

The 15 Most Densely Populated Countries in the World

The 10 Biggest Tea Drinking Countries in the World

Top 6 Ways to Improve Your Checkout Process and Close Sales

The 5 Most Profitable Online Businesses You Can Start Today

The 20 Most Profitable Hospitals in the US

The 5 Most Profitable Home Businesses to Start

The 7 Teams that Will Win the Stanley Cup in 2015

The Top 10 Most Expensive Digital Cameras to Snap Stunning Shots With

The 10 Highest Quality Fast Food Restaurants In America Today

The 8 Best Halloween Decorating Ideas to Spook Up Your House

10 Marvel Women that Should Get a Movie Right Now

The 20 Best Remixes of Popular Songs that Will Make You Forget the Originals

7 Most Expensive Cities in the World

5 Least Expensive Cities in the World

10 Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!